Brief: Celcuity Announces Positive Topline Results From PIK3CA Wild-Type Cohort Of Phase 3 VIKTORIA-1 Clinical Trial
28/07/2025 11:00
July 28 (Reuters) - Celcuity Inc CELC.O: CELCUITY: GEDATOLISIB + FULVESTRANT REDUCED RISK OF PROGRESSION OR DEATH BY 67% VERSUS. FULVESTRANT CELCUITY: TOPLINE DATA FOR VIKTORIA-1 PIK3CA MUTATION COHORT IS EXPECTED BY END OF 2025 CELCUITY: EXPECTS TO SUBMIT NEW DRUG APPLICATION FOR GEDATOLISIB TO U.S. FDA IN Q4 2025 CELCUITY: CLINICALLY MEANINGFUL IMPROVEMENT IN BOTH PFS PRIMARY ENDPOINTS FROM PIK3CA WILD-TYPE COHORT OF PHASE 3 VIKTORIA-1 TRIAL CELCUITY: GEDATOLISIB + PALBOCICLIB + FULVESTRANT REDUCED RISK OF DISEASE PROGRESSION OR DEATH BY 76% VERSUS. FULVESTRANT Further company coverage: CELC.O ((Reuters.Briefs@thomsonreuters.com;))